Healing & Recovery
Do Stem Cell Injections Work for Joint Injury?
The short answer
The evidence is real but thinner and more mixed than the marketing suggests. Almost all of it comes from knee osteoarthritis, not acute joint injury, and most of the underlying trials are small — of 124 mesenchymal stem cell (MSC) trials registered for knee osteoarthritis on ClinicalTrials.gov, the majority are early-phase with fewer than 100 participants, several never reported results, and some were withdrawn. Pain improvement shows up fairly consistently across meta-analyses: a 2026 review of 6 randomized trials (551 patients) found significant reductions in pain and WOMAC scores through 12 months, and a 2024 meta-analysis found MSC injections beat hyaluronic acid on pain, function, and MRI cartilage scores at 12 months. But a broader 2026 meta-analysis of 28 trials found pain improved while overall function (WOMAC), quality of life, and MRI-based structural scores did not — concluding MSC therapy looks 'symptom-modifying rather than structure-modifying.' Local reactions like injection-site pain and joint swelling were consistently more common with MSC than control.
Quick answers
- What is it?
- Whether stem cell (mesenchymal stem cell) injections actually work for joint injury.
- Why are people interested in it?
- Stem cell injections are marketed as a cutting-edge treatment for joint problems, and people want to know if the evidence supports that for injuries, not just arthritis.
- What has actually been studied?
- A ClinicalTrials.gov search of 124 registered mesenchymal stem cell trials for knee osteoarthritis, plus several meta-analyses ranging from 6 to 28 randomized trials and 551 to 818 patients, comparing MSC injections against placebo, hyaluronic acid, or other controls.
- How strong is the evidence?
- Multiple meta-analyses of randomized trials, but almost all evidence is in chronic knee osteoarthritis rather than acute joint injury, and most underlying trials are small, early-phase, and methodologically uneven.
- What don't we know yet?
- Whether any of this applies to acute joint injury rather than chronic osteoarthritis, which cell source/dose/preparation matters, why structural MRI results disagree between reviews, how much benefit reflects blinding failure or placebo response, and long-term outcomes and funding-source transparency.
- Where can I read the original research?
- Sources at the bottom of this page: Han JH, Jung M, Chung K, et al. Autologous adipose-derived mesenchymal stromal cell injection for knee osteoarthritis improves pain and function without a clear increase in adverse events; Awad G, Saad JP, Hamyeh A, Boutros M. Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis.
The short answer: Stem cell injections for joints — almost exclusively studied in chronic knee osteoarthritis rather than acute injury — show a real but inconsistent pattern across the published trials: pain relief shows up fairly often, meaningful gains in overall function and joint structure show up less often, and much of the underlying evidence base is small, short-term, and methodologically uneven. Local side effects like injection-site pain and joint swelling are consistently more common than with control treatments, though serious complications remain rare.
What the research shows
The trial landscape is smaller and earlier-stage than the marketing implies
A search of ClinicalTrials.gov for mesenchymal stem cell (MSC) interventions in knee osteoarthritis returns 124 registered studies. Scanning through them, a pattern emerges: enrollments of 4, 6, 10, 11, 30, or 38 participants are common, many are labeled phase 1 or phase 1/2, several carry a status of "unknown" (meaning no results were ever reported after the listed completion date), and at least one was withdrawn before enrolling anyone. This matters for interpreting the meta-analyses below — they are pooling from a base of mostly small, often single-center, often unblinded studies, not a deep bench of large confirmatory trials.
Where the evidence looks best: pain, and a head-to-head win over hyaluronic acid
The most favorable results come from comparisons against an active competitor rather than placebo. A 2024 meta-analysis pooled 10 randomized trials (818 patients) comparing MSC injection directly against hyaluronic acid (HA), a standard viscosupplement. At 12 months, MSC outperformed HA on WOMAC total score (mean difference −10.22, 95% CI −14.86 to −5.59), pain (VAS, MD −1.31), and — notably — on the Whole-Organ MRI Score (WORMS), a structural cartilage measure (MD −26.01), all reaching thresholds considered clinically meaningful. Adverse event rates were similar between groups. A 2026 meta-analysis focused specifically on autologous adipose-derived stem cells (6 trials, 551 patients) found similarly consistent pain and WOMAC improvements at 3, 6, and 12 months compared with control, without a significant increase in overall adverse events.
Where it looks weaker: function and joint structure, more broadly
A larger and more recent 2026 meta-analysis cast a wider net, pooling 28 randomized trials of intra-articular MSC therapy against various controls. Pain outcomes again looked favorable (change in VAS, MD −1.67; KOOS pain, MD +15.37, both statistically significant). But several function-related measures — the WOMAC total score, KOOS quality-of-life subscale, and Lequesne Index — showed no significant difference from control. MRI-based structural scores (WORMS) were also not significantly improved. The authors' summary was direct: current evidence suggests MSC therapy plays "a primarily symptom-modifying rather than structure-modifying role." This sits somewhat at odds with the HA-comparison trial above, which did find a structural signal — a reminder that results shift depending on what MSC is being compared against (placebo/saline versus an active alternative like HA) and which specific cell products and doses were pooled.
A separate 2025 meta-analysis focused on adipose- and bone marrow-derived cells compared against other orthobiologic injections (not placebo), pooling 10 studies and 563 patients. It again found significant pain reductions at 3, 6, and 12 months — but concluded these pain gains "did not correspond to substantial improvements in knee functionality." That same paper flagged a statistically significant sign of publication bias in its pooled data (Egger's test, p=0.007) and rated two of its ten included studies as high risk of bias — a direct, quantified example of the kind of quality problem this field is known for.
Dosing frequency and safety
A 2025 network meta-analysis specifically compared single versus repeated MSC injections across 16 trials (622 patients). Repeated injections produced larger improvements in pain and function scores at 6 and 12 months than a single injection — but also came with a higher rate of adverse events, mostly local reactions. On safety broadly, the 2026 meta-analysis of 28 trials found MSC injection carried a significantly higher relative risk of injection-site pain (RR 2.04) and joint swelling (RR 3.39) compared with control, along with a modestly elevated risk of adverse events overall (RR 1.26). Serious complications, including infection, remained uncommon and were not statistically elevated in the pooled data — but "uncommon" in a literature built mostly from small trials is not the same as "well-characterized."
What we don't know yet
Whether any of this applies to acute joint injury rather than chronic osteoarthritis. Nearly every trial identified in this search enrolled patients with established knee osteoarthritis, not people recovering from an acute ligament, meniscus, or cartilage injury — the population many people asking about "stem cells for joint injury" actually have in mind.
Which cell source, dose, and preparation method actually matters. Trials pooled in these meta-analyses used adipose-derived, bone marrow-derived, and other MSC sources, at different cell counts and with different processing methods, without a standardized reference product to compare them against.
Why structural (MRI cartilage) results disagree between reviews. One meta-analysis comparing MSC against hyaluronic acid found a significant structural benefit; a broader meta-analysis comparing MSC against mixed controls did not. Neither retrieved study reconciles this directly.
How much of the observed benefit reflects blinding failure or placebo response. Few of the pooled trials used a true sham-injection control, and the ClinicalTrials.gov landscape confirms most studies never reached the scale or design rigor needed to rule this out.
Long-term outcomes and funding sources. The reviewed meta-analyses topped out around 12 months of follow-up, and the underlying trial registry shows multiple industry-sponsored, single-arm, or unpublished studies whose funding relationships were not consistently reported in the pooled analyses.
Sources
- Han JH, Jung M, Chung K, Moon HS, Jung SH, Baik SH, Koo J, Sim W, Kim SH. Autologous adipose-derived mesenchymal stromal cell injection for knee osteoarthritis improves pain and function without a clear increase in adverse events: A systematic review and meta-analysis of randomized controlled trials. Knee Surgery, Sports Traumatology, Arthroscopy, 2026. DOI
- Awad G, Saad JP, Hamyeh A, Boutros M. Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. Clinical Rheumatology, 2026;45(5):2905-2942. DOI
- Hohmann E, Keough N, Stokes D, Frank R, Rodeo S. Adipose- and bone marrow-derived stromal cells reduce pain in patients with knee osteoarthritis but do not substantially improve knee functionality: an updated systematic review and meta-analysis. European Journal of Orthopaedic Surgery & Traumatology, 2025;35(1):214. DOI
- Jin WS, Yin LX, Sun HQ, Zhao Z, Yan XF. Mesenchymal Stem Cells Injection Is More Effective Than Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis With Similar Safety: A Systematic Review and Meta-analysis. Arthroscopy, 2024;41(2):318-332. DOI
- Deng L, Zhao C, Zhou L, Mu X, Sun H, Li L, Zhang Y. Efficacy and safety of single versus repeated injections of mesenchymal stem cells for the treatment of knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials. Stem Cell Research & Therapy, 2025;16(1):505. DOI
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Recovery & Tissue Research
Sources
- Autologous adipose-derived mesenchymal stromal cell injection for knee osteoarthritis improves pain and function without a clear increase in adverse events: A systematic review and meta-analysis of randomized controlled trials
- Knee Surgery, Sports Traumatology, Arthroscopy, 2026 · n=551 · DOI
- Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials
- Clinical Rheumatology, 2026 · DOI
- Adipose- and bone marrow-derived stromal cells reduce pain in patients with knee osteoarthritis but do not substantially improve knee functionality: an updated systematic review and meta-analysis
- European Journal of Orthopaedic Surgery & Traumatology, 2025 · n=563 · DOI
- Mesenchymal Stem Cells Injection Is More Effective Than Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis With Similar Safety: A Systematic Review and Meta-analysis
- Arthroscopy, 2024 · n=818 · DOI
- Efficacy and safety of single versus repeated injections of mesenchymal stem cells for the treatment of knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials
- Stem Cell Research & Therapy, 2025 · n=622 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.